Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: Relevance for paclitaxel transport

Biomedicine and Pharmacotherapy

Volumn 65, Issue 6, 2011, Pages 417-426

  Svoboda, Martin ^a   Wlcek, Katrin ^b   Taferner, Barbara ^b   Hering, Steffen ^b   Stieger, Bruno ^c   Tong, Dan ^d   Zeillinger, Robert ^d   Thalhammer, Theresia ^a   Jäger, Walter ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

Author keywords

OATPs; Ovarian cancer; OVCAR 3; Paclitaxel; PCR; SK OV 3

Indexed keywords

MESSENGER RNA; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 1B3; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CELL ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG UPTAKE; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IC 50; NUCLEOTIDE SEQUENCE; OOCYTE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOPUS LAEVIS;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; OOCYTES; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; OVARIAN NEOPLASMS; PACLITAXEL; RECOMBINANT PROTEINS; RNA, MESSENGER; XENOPUS LAEVIS;

EID: 80052675543     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.04.031     Document Type: Article

References (48)

1. DiSaia P.J., Creasman W.T. Epithelial ovarian cancer. Clinical gynecologic oncology 2002, 289-350. Mosby-Year Book, St. Louis. 6th ed. P.J. DiSaia, W.T. Creasman (Eds.).
2. Permuth-Wey J., Sellers T.A. Epidemiology of ovarian cancer. Methods Mol Biol 2009, 472:413-437.
3. Rowinsky E.K., Donehower R.C. Paclitaxel (taxol). N Engl J Med 1995, 332:1004-1014.
4. Agarwal R., Kaye S.B. Ovarian cancer: strategies for overcoming resistance tochemotherapy. Nat Rev Cancer 2003, 3:502-516.
5. Markman M. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. Trends Pharmacol Sci 2008, 29:515-519.
6. Baekelandt M.M., Holm R., Nesland J.M., Tropé C.G., Kristensen G.B. P-glycoproteinexpression is a marker for chemotherapy resistance and prognosis in advancedovarian cancer. Anticancer Res 2000, 20:1061-1067.
7. Kamazawa S., Kigawa J., Kanamori Y., Itamochi H., Sato S., Iba T., et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 2002, 86:171-176.
8. Huisman M.T., Chhatta A.A., van Tellingen O., Beijnen J.H., Schinkel A.H. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 2005, 116:824-829.
9. O'Brien C., Cavet G., Pandita A., Hu X., Haydu L., Mohan S., et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res 2008, 68:5380-5389.
10. Oguri T., Ozasa H., Uemura T., Bessho Y., Miyazaki M., Maeno K., et al. MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther 2008, 7:1150-1155.
11. Dobson P.D., Kell D.B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?. Nat Rev Drug Discov 2008, 7:205-220.
12. Hagenbuch B., Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 2008, 38:778-801.
13. Kim R.B. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 2003, 33(Suppl. 2):1-5.
14. Hagenbuch B., Meier P.J. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004, 447:653-665.
15. Tamai I., Nezu J., Uchino H., Sai Y., Oku A., Shimane M., et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000, 273:251-260.
16. Muto M., Onogawa T., Suzuki T., Ishida T., Rikiyama T., Katayose Y., et al. Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci 2007, 98:1570-1576.
17. Wlcek K., Svoboda M., Thalhammer T., Sellner F., Krupitza G., Jaeger W. Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma. Cancer Biol Ther 2008, 7:1450-1455.
18. Mikkaichi T., Suzuki T., Tanemoto M., Ito S., Abe T. The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 2004, 19:171-179.
19. Abe T., Unno M., Onogawa T., Tokui T., Kondo T.N., Nakagomi R., et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001, 120:1689-1699.
20. Okabe M., Unno M., Harigae H., Kaku M., Okitsu Y., Sasaki T., et al. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 2005, 333:754-762.
21. Ciarimboli G., Ludwig T., Lang D., Pavenstädt H., Koepsell H., Piechota H.J., et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005, 167:1477-1484.
22. Yonezawa A., Masuda S., Yokoo S., Katsura T., Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006, 319:879-886.
23. Zhang S., Lovejoy K.S., Shima J.E., Lagpacan L.L., Shu Y., Lapuk A., et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006, 66:8847-8857.
24. Okabe M., Szakács G., Reimers M.A., Suzuki T., Hall M.D., Abe T., et al. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 2008, 7:3081-3091.
25. Smith N.F., Acharya M.R., Desai N., Figg W.D., Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005, 4:815-818.
26. van de Steeg E., van Esch A., Wagenaar E., van der Kruijssen C.M., van Tellingen O., Kenworthy K.E., et al. High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res 2011, 17:294-301.
27. Kobayashi Y., Ohshiro N., Sakai R., Ohbayashi M., Kohyama N., Yamamoto T. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 2005, 57:573-578.
28. Sekine T., Cha S.H., Tsuda M., Apiwattanakul N., Nakajima N., Kanai Y., et al. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett 1998, 429:179-182.
29. Kang S.K., Choi K.C., Tai C.J., Auersperg N., Leung P.C. Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. Endocrinology 2001, 142:580-588.
30. Keith Bechtel M., Bonavida B. Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for nducible nitric oxide synthase. Gynecol Oncol 2001, 82:127-138.
31. Shepherd J.H. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989, 96:889-892.
32. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
33. Kullak-Ublick G.A., Ismair M.G., Stieger B., Landmann L., Huber R., Pizzagalli F., et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001, 120:525-533.
34. Khom S., Baburin I., Timin E.N., Hohaus A., Sieghart W., Hering S. Pharmacological properties of GABAA receptors containing gamma1 subunits. Mol Pharmacol 2006, 69:640-649.
35. Bianchi L., Driscoll M. Heterologous expression of C. elegans ion channels in Xenopus oocytes. WormBook 2006, 1:1-16.
36. Cui Y., König J., Nies A.T., Pfannschmidt M., Hergt M., Franke W.W., et al. Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab Invest 2003, 83:527-538.
37. Hirano M., Maeda K., Shitara Y., Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004, 311:139-146.
38. Takano M., Otani Y., Tanda M., Kawami M., Nagai J., Yumoto R. Paclitaxel-resistance conferred by altered expression of efflux and influx transporters for paclitaxel in the human hepatoma cell line, HepG2. Drug Metab Pharmacokinet 2009, 24:418-427.
39. Gui C., Miao Y., Thompson L., Wahlgren B., Mock M., Stieger B., et al. Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 2008, 584:57-65.
40. Smith N.F., Marsh S., Scott-Horton T.J., Hamada A., Mielke S., Mross K., et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007, 81:76-82.
41. Picard N., Yee S.W., Woillard J.B., Lebranchu Y., Le Meur Y., Giacomini K.M., et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 2010, 87:100-108.
42. Sonnichsen D.S., Relling M.V. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 1994, 27:256-269.
43. Gui C., Obaidat A., Chaguturu R., Hagenbuch B. Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics 2010, 4:1-8.
44. Jung D., Hagenbuch B., Gresh L., Pontoglio M., Meier P.J., Kullak-Ublick G.A. Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha. J Biol Chem 2001, 276:37206-37214.
45. Tomassetti A., De Santis G., Castellano G., Miotti S., Mazzi M., Tomasoni D., et al. Variant HNF1 modulates epithelial plasticity of normal and transformed ovary cells. Neoplasia 2008, 10:1481-1492. [3p following 1492].
46. König J., Seithel A., Gradhand U., Fromm M.F. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006, 372:432-443.
47. Seithel A., Eberl S., Singer K., Auge D., Heinkele G., Wolf N.B., et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007, 35:779-786.
48. Treiber A., Schneiter R., Häusler S., Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 2007, 35:1400-1407.